{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:58:54Z","timestamp":1790467134972,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"DOI":"10.1007\/s40290-026-00622-0","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:42:38Z","timestamp":1790419358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Galenic Modification as an Alternative Strategy for Administering Oral Anticancer Drugs: Assessment of Bioequivalence"],"prefix":"10.1007","author":[{"given":"Pauline","family":"Claraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Pineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Guillemot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Chatelut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-5784","authenticated-orcid":false,"given":"Florent","family":"Puisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"issue":"6","key":"622_CR1","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.otc.2013.08.008","volume":"46","author":"DF Roden","year":"2013","unstructured":"Roden DF, Altman KW. Causes of dysphagia among different age groups. Otolaryngol Clin North Am. 2013;46(6):965\u201387. https:\/\/doi.org\/10.1016\/j.otc.2013.08.008.","journal-title":"Otolaryngol Clin North Am"},{"issue":"10","key":"622_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/j.1365-2036.2008.03664.x","volume":"27","author":"GD Eslick","year":"2008","unstructured":"Eslick GD, Talley NJ. Dysphagia: epidemiology, risk factors and impact on quality of life\u2014a population-based study. Aliment Pharmacol Ther. 2008;27(10):971\u20139. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03664.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"622_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-023-01268-4","volume":"22","author":"DNM Silva","year":"2023","unstructured":"Silva DNM, Vicente LCC, Gl\u00f3ria VLP, de Lima Friche AA. Swallowing disorders and mortality in adults with advanced cancer outside the head and neck and upper gastrointestinal tract: a systematic review. BMC Palliat Care. 2023;22(1):150. https:\/\/doi.org\/10.1186\/s12904-023-01268-4.","journal-title":"BMC Palliat Care"},{"issue":"3","key":"622_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1378\/chest.09-1823","volume":"137","author":"SA Skoretz","year":"2010","unstructured":"Skoretz SA, Flowers HL, Martino R. The incidence of dysphagia following endotracheal intubation: a systematic review. Chest. 2010;137(3):665\u201373. https:\/\/doi.org\/10.1378\/chest.09-1823.","journal-title":"Chest"},{"issue":"9","key":"622_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jamda.2018.03.016","volume":"19","author":"R Wirth","year":"2018","unstructured":"Wirth R, Pourhassan M, Streicher M, Hiesmayr M, Schindler K, Sieber CC, et al. The impact of dysphagia on mortality of nursing home residents: results from the nutritionDay Project. J Am Med Dir Assoc. 2018;19(9):775\u20138. https:\/\/doi.org\/10.1016\/j.jamda.2018.03.016.","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"622_CR6","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.02.011","volume":"28","author":"MC Feng","year":"2019","unstructured":"Feng MC, Lin YC, Chang YH, Chen CH, Chiang HC, Huang LC, et al. The mortality and the risk of aspiration pneumonia related with dysphagia in stroke patients. J Stroke Cerebrovasc Dis. 2019;28(5):1381\u20137. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2019.02.011.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"10","key":"622_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40266-023-01056-y","volume":"40","author":"A Blaszczyk","year":"2023","unstructured":"Blaszczyk A, Brandt N, Ashley J, Tuders N, Doles H, Stefanacci RG. Crushed tablet administration for patients with dysphagia and enteral feeding: challenges and considerations. Drugs Aging. 2023;40(10):895\u2013907. https:\/\/doi.org\/10.1007\/s40266-023-01056-y.","journal-title":"Drugs Aging"},{"issue":"2","key":"622_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1592\/phco.31.2.164","volume":"31","author":"MSH Lam","year":"2011","unstructured":"Lam MSH. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. Pharmacotherapy. 2011;31(2):164\u201392. https:\/\/doi.org\/10.1592\/phco.31.2.164.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"622_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.7399\/fh.11628","volume":"45","author":"E Tejedor-Tejada","year":"2021","unstructured":"Tejedor-Tejada E, Nieto-Guindo P, Tejedor-Tejada J, Mart\u00ednez-Velasco E, G\u00f3mez-S\u00e1nchez A. A guide for the administration of oral antineoplastic in patients with swallowing disorders. Farm Hosp. 2021;45(3):126\u201334. https:\/\/doi.org\/10.7399\/fh.11628.","journal-title":"Farm Hosp"},{"issue":"11","key":"622_CR10","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/jac5.1698","volume":"5","author":"J Cohen","year":"2022","unstructured":"Cohen J, Lee C, Markham R, Szerwo J, Roska M, Bubalo J. Medication use process and assessment of extemporaneous compounding and alternative routes of administration of oral oncology drugs: guidance for clinical and oncology pharmacists. JACCP J Am Coll Clin Pharm. 2022;5(11):1176\u2013228. https:\/\/doi.org\/10.1002\/jac5.1698.","journal-title":"JACCP J Am Coll Clin Pharm."},{"issue":"9\u201310","key":"622_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.drudis.2011.11.007","volume":"17","author":"L Di","year":"2012","unstructured":"Di L, Fish PV, Mano T. Bridging solubility between drug discovery and development. Drug Discov Today. 2012;17(9\u201310):486\u201395. https:\/\/doi.org\/10.1016\/j.drudis.2011.11.007.","journal-title":"Drug Discov Today"},{"issue":"3","key":"622_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"H Lennern\u00e4s","year":"1995","unstructured":"Lennern\u00e4s H, Shah VP, Crison JR, Amidon GL. A Theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413\u201320. https:\/\/doi.org\/10.1023\/A:1016212804288.","journal-title":"Pharm Res"},{"issue":"6","key":"622_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/BF02976347","volume":"18","author":"DM Oh","year":"1995","unstructured":"Oh DM, Curl RL, Yong CS, Amidon GL. Effect of micronization on the extent of drug absorption from suspensions in humans. Arch Pharm Res. 1995;18(6):427\u201333. https:\/\/doi.org\/10.1007\/BF02976347.","journal-title":"Arch Pharm Res"},{"key":"622_CR14","unstructured":"ICH M13A Guideline on bioequivalence for immediate-release solid oral dosage forms_Step 5."},{"key":"622_CR15","unstructured":"Committee for Medicinal Products for Human Use, (CHMP). Guideline on the investigation of bioequivalence [Internet]. EMA; 2010. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf."},{"issue":"4","key":"622_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/1120009X.2024.2354621","volume":"37","author":"E Tejedor Tejada","year":"2025","unstructured":"Tejedor Tejada E, Gonzalez Su\u00e1rez S, Lizondo L\u00f3pez T, L\u00f3pez-Cabezas C, Soy Muner D. Alternatives for the administration of oral antineoplastics in patients with swallowing difficulties. J Chemother. 2025;37(4):293\u2013306. https:\/\/doi.org\/10.1080\/1120009X.2024.2354621.","journal-title":"J Chemother"},{"key":"622_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122834","author":"EC Bernsen","year":"2022","unstructured":"Bernsen EC, Hogenes VJ, Nuijen B, Hanff LM, Huitema ADR, Diekstra MHM. Practical recommendations for the manipulation of kinase inhibitor formulations to age-appropriate dosage forms. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14122834.","journal-title":"Pharmaceutics"},{"key":"622_CR18","unstructured":"ICH M9 on biopharmaceutics classification system based biowaivers - Scientific guideline | European Medicines Agency (EMA) [Internet]. 2018 [cited 2025 May 20]. Available from: https:\/\/www.ema.europa.eu\/en\/ich-m9-biopharmaceutics-classification-system-based-biowaivers-scientific-guideline."},{"key":"622_CR19","unstructured":"Boehringer Ingelheim. Gilotrif\u2014afatinib, film-coated tablets - Clinical Pharmacology Review. Center for Drug Evaluation and Research-FDA; 2012."},{"key":"622_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14091830","author":"Y Qin","year":"2022","unstructured":"Qin Y, Xiao C, Li X, Huang J, Si L, Sun M. Enteric polymer\u2013based amorphous solid dispersions enhance oral absorption of the weakly basic drug nintedanib via stabilization of supersaturation. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14091830.","journal-title":"Pharmaceutics"},{"issue":"3","key":"622_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","volume":"56","author":"S Wind","year":"2017","unstructured":"Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P. Clinical pharmacokinetics and pharmacodynamics of afatinib. Clin Pharmacokinet. 2017;56(3):235\u201350. https:\/\/doi.org\/10.1007\/s40262-016-0440-1.","journal-title":"Clin Pharmacokinet"},{"key":"622_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejps.2014.09.004","volume":"65","author":"A Garc\u00eda-Arieta","year":"2014","unstructured":"Garc\u00eda-Arieta A. Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: Impact on bioequivalence. Eur J Pharm Sci. 2014;65:89\u201397. https:\/\/doi.org\/10.1016\/j.ejps.2014.09.004.","journal-title":"Eur J Pharm Sci"},{"key":"622_CR23","unstructured":"Centocor Ortho Biotech Inc. Zytiga\u2014abiraterone acetate, 250 mg immediate release tablet\u2014clinical pharmacology review. Center for Drug Evaluation and Research-FDA; 2010."},{"key":"622_CR24","doi-asserted-by":"publisher","DOI":"10.18433\/J39W3V","author":"YJ Manrique-Torres","year":"2014","unstructured":"Manrique-Torres YJ, Lee DJ, Islam F, Nissen LM, Cichero JAY, Stokes JR, et al. Crushed tablets: does the administration of food vehicles and thickened fluids to aid medication swallowing alter drug release? J Pharm Pharm Sci. 2014. https:\/\/doi.org\/10.18433\/J39W3V.","journal-title":"J Pharm Pharm Sci"},{"issue":"1","key":"622_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.0306-5251.2001.temp.1441.x","volume":"52","author":"GT Tucker","year":"2001","unstructured":"Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism\/transporter interaction potential\u2014towards a consensus. Br J Clin Pharmacol. 2001;52(1):107\u201317. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.temp.1441.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"622_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/1078155219841108","volume":"26","author":"J Stein","year":"2020","unstructured":"Stein J, Milhem M, Vaena D. Clinical outcomes and toxicities of pazopanib administered orally in crushed form: case reports and review of the literature. J Oncol Pharm Pract. 2020;26(1):232\u20135. https:\/\/doi.org\/10.1177\/1078155219841108.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"622_CR27","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/j.cllc.2023.12.013","volume":"25","author":"C Jang","year":"2024","unstructured":"Jang C, Lau SC, Velcheti V. To crush or not to crush: administering dabrafenib and trametinib through a nasogastric tube in a critically ill patient with nonsmall cell lung cancer\u2014a case report and review of literature of targeted therapies given through enteral feeding tubes. Clin Lung Cancer. 2024;25(3):e124\u20138. https:\/\/doi.org\/10.1016\/j.cllc.2023.12.013.","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"622_CR28","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1177\/1078155218793197","volume":"25","author":"MT Bejarano Varas","year":"2019","unstructured":"Bejarano Varas MT, Gould S, Charlot M. Response to alectinib oil-based suspension in anaplastic lymphoma kinase-positive non-small cell lung cancer in a patient unable to swallow: a case report. J Oncol Pharm Pract. 2019;25(7):1722\u20135. https:\/\/doi.org\/10.1177\/1078155218793197.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"622_CR29","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s10637-011-9725-2","volume":"30","author":"EI Heath","year":"2012","unstructured":"Heath EI, Forman K, Malburg L, Gainer S, Suttle AB, Adams L, et al. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Invest New Drugs. 2012;30(4):1566\u201374. https:\/\/doi.org\/10.1007\/s10637-011-9725-2.","journal-title":"Invest New Drugs"},{"issue":"2","key":"622_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/JTO.0b013e3182746772","volume":"8","author":"HK Ahn","year":"2013","unstructured":"Ahn HK, Jeon K, Yoo H, Han B, Lee SJ, Park H, et al. Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer. J Thorac Oncol. 2013;8(2):250\u20133. https:\/\/doi.org\/10.1097\/JTO.0b013e3182746772.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"622_CR31","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/cpdd.1001","volume":"10","author":"A Yu","year":"2021","unstructured":"Yu A, Erba M, Hazra A. Pharmacokinetics and use-testing of apalutamide prepared in aqueous food vehicles for alternative administration. Clin Pharmacol Drug Dev. 2021;10(11):1375\u201384. https:\/\/doi.org\/10.1002\/cpdd.1001.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"622_CR32","unstructured":"Ligand Pharmaceuticals UK Limited. Targretin: EPAR - Public assessment report. EMA; 2021."},{"key":"622_CR33","unstructured":"Pfizer Ltd. Bosulif: EPAR - Public assessment report. EMA; 2013."},{"key":"622_CR34","unstructured":"Exelixis, Inc. Cabometyx - Cabozantinib, oral tablets\u2014clinical pharmacology review. Center for Drug Evaluation and Research-FDA; 2015."},{"issue":"11","key":"622_CR35","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1093\/annonc\/mdn662","volume":"19","author":"L Chaigneau","year":"2008","unstructured":"Chaigneau L, Royer B, Montange D, Nguyen T, Maurina T, Villanueva C, et al. Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study. Ann Oncol. 2008;19(11):1980\u20131. https:\/\/doi.org\/10.1093\/annonc\/mdn662.","journal-title":"Ann Oncol"},{"issue":"24","key":"622_CR36","doi-asserted-by":"publisher","first-page":"7294","DOI":"10.1158\/1078-0432.CCR-17-3572","volume":"25","author":"MW Kieran","year":"2019","unstructured":"Kieran MW, Geoerger B, Dunkel IJ, Broniscer A, Hargrave D, Hingorani P, et al. A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors. Clin Cancer Res. 2019;25(24):7294\u2013302. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3572.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"622_CR37","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.xphs.2018.11.005","volume":"108","author":"S Vaidhyanathan","year":"2019","unstructured":"Vaidhyanathan S, Wang X, Crison J, Varia S, Gao JZH, Saxena A, et al. Bioequivalence comparison of pediatric dasatinib formulations and elucidation of absorption mechanisms through integrated PBPK modeling. J Pharm Sci. 2019;108(1):741\u20139. https:\/\/doi.org\/10.1016\/j.xphs.2018.11.005.","journal-title":"J Pharm Sci"},{"key":"622_CR38","unstructured":"Janssen Research & Development. Balversa - Erdafitinib, tablets\u2014multidiscipline review. Center for Drug Evaluation and Research-FDA; 2018."},{"issue":"2","key":"622_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/0091270002239822","volume":"43","author":"JM Kovarik","year":"2003","unstructured":"Kovarik JM, Noe A, Berthier S, McMahon L, Langholff WK, Marion AS, et al. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. J Clin Pharmacol. 2003;43(2):141\u20137. https:\/\/doi.org\/10.1177\/0091270002239822.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"622_CR40","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.clinthera.2004.10.011","volume":"26","author":"MV Cantarini","year":"2004","unstructured":"Cantarini MV, McFarquhar T, Smith RP, Bailey C, Marshall AL. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. Clin Ther. 2004;26(10):1630\u20136. https:\/\/doi.org\/10.1016\/j.clinthera.2004.10.011.","journal-title":"Clin Ther"},{"key":"622_CR41","unstructured":"Pharmacyclics. Imbruvica - Ibrutinib, 140 mg capsules\u2014clinical pharmacology review. Center for Drug Evaluation and Research-FDA; 2013."},{"key":"622_CR42","unstructured":"Novartis pharmaceutical corp. Gleevec - imatinib, oral hard gelatine capsules, 50 and 100 mg\u2014clinical pharmacology review. Center for Drug Evaluation and Research-FDA; 2001."},{"issue":"3","key":"622_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/cpdd.139","volume":"4","author":"KM Koch","year":"2015","unstructured":"Koch KM, Ferron-Brady G, Lemmon C, Cartee L, Hollyfield H, D\u2019Amelio AM, et al. Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients. Clin Pharmacol Drug Dev. 2015;4(3):203\u20139. https:\/\/doi.org\/10.1002\/cpdd.139.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"622_CR44","unstructured":"Loxo Oncology, Inc. Vitrakvi - larotrectinib, capsule: 25 mg, 100 mg; solution: 20mg\/mL\u2014NDA multi-disciplinary review and evaluation. Center for Drug Evaluation and Research-FDA; 2018."},{"key":"622_CR45","unstructured":"Pfizer, Inc. Lorbrena - lorlatinib, 100 mg and 25 mg tablets\u2014NDA multi-disciplinary review and evaluation. Center for Drug Evaluation and Research-FDA; 2017."},{"key":"622_CR46","unstructured":"Nova Laboratories, Ltd. Purixan-mercaptopurine, 20 mg\/ml oral suspension\u2014clinical pharmacology review. Center for Drug Evaluation and Research-FDA; 2013."},{"key":"622_CR47","unstructured":"Silvergate Pharmaceuticals, Inc. Xatmep - methotrexate, 2.5 mg\/ml oral solution\u2014clinical pharmacology review. Center for Drug Evaluation and Research-FDA; 2015."},{"key":"622_CR48","unstructured":"Novartis. Rydapt - Midostaurin, soft capsules, 25 mg\u2014clinical pharmacology review. Center for Drug Evaluation and Research-FDA; 2016."},{"key":"622_CR49","unstructured":"Ligand Pharmaceuticals UK Limited. Nerlynx: EPAR\u2014public assessment report. EMA; 2018."},{"issue":"11","key":"622_CR50","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1177\/0091270010384116","volume":"51","author":"OQP Yin","year":"2011","unstructured":"Yin OQP, Rudoltz M, Galetic I, Filian J, Krishna A, Zhou W, et al. Effects of yogurt and applesauce on the oral bioavailability of nilotinib in healthy volunteers. J Clin Pharmacol. 2011;51(11):1580\u20136. https:\/\/doi.org\/10.1177\/0091270010384116.","journal-title":"J Clin Pharmacol"},{"key":"622_CR51","unstructured":"Boehringer Ingelheim, Inc. Ofev - nintedanib, capsule; 150 mg and 100 mg\u2014clinical pharmacology and biopharmaceutics review(s). Center for Drug Evaluation and Research-FDA; 2014."},{"key":"622_CR52","unstructured":"AstraZeneca Pharmaceuticals. Tagrisso - Osimertinib, 40 mg and 80 mg tablets\u2014clinical pharmacology review. Center for Drug Evaluation and Research-FDA; 2015."},{"key":"622_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/CPAA.S171735","volume":"10","author":"Y Li","year":"2018","unstructured":"Li Y, Liu L, Huang L, Wang X, Hoffmann M, Reyes J, et al. A Phase I, open-label, randomized, crossover study in healthy subjects to evaluate the bioavailability of, and the food effect on, a pomalidomide oral liquid suspension. CPAA. 2018;10:89\u201399. https:\/\/doi.org\/10.2147\/CPAA.S171735.","journal-title":"CPAA."},{"key":"622_CR54","unstructured":"Bayer HealthCare Pharmaceuticals, Inc. Stivarga - regorafenib, 40 mg film-coated tablet\u2014clinical pharmacology review. Center for Drug Evaluation and Research-FDA; 2012."},{"key":"622_CR55","unstructured":"Karyopharm Therapeutics. Xpovio - Selinexor, 20 mg, immediate-release tablet\u2014multidiscipline review. Center for Drug Evaluation and Research-FDA; 2018."},{"issue":"5","key":"622_CR56","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","volume":"16","author":"U Banerji","year":"2010","unstructured":"Banerji U, Camidge DR, Verheul HMW, Agarwal R, Sarker D, Kaye SB, et al. The first-in-human study of the hydrogen sulfate (Hyd-Sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I Open-Label Multicenter Trial in patients with advanced cancer. Clin Cancer Res. 2010;16(5):1613\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2483.","journal-title":"Clin Cancer Res"},{"issue":"15 suppl","key":"622_CR57","doi-asserted-by":"publisher","first-page":"e14549","DOI":"10.1200\/jco.2009.27.15_suppl.e14549","volume":"27","author":"JT Lettieri","year":"2009","unstructured":"Lettieri JT, Dubowy R, Xia C, Rotolo C, Zinny MA. Bioavailability of sorafenib tablets administered as a liquid suspension. JCO. 2009;27(15 suppl):e14549\u2013e14549. https:\/\/doi.org\/10.1200\/jco.2009.27.15_suppl.e14549.","journal-title":"JCO"},{"key":"622_CR58","unstructured":"P. Cardona, BH. An open\u2010label study to evaluate the relative bioavailability of sotorasib administered as tablets or as a water dispersion in healthy subjects. In: Clinical pharmacology and therapeutics. 2022. p. S11."},{"issue":"8","key":"622_CR59","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40261-022-01172-4","volume":"42","author":"M Badawi","year":"2022","unstructured":"Badawi M, Chen X, Marroum P, Suleiman AA, Mensing S, Koenigsdorfer A, et al. Bioavailability evaluation of venetoclax lower-strength tablets and oral powder formulations to establish interchangeability with the 100 mg tablet. Clin Drug Investig. 2022;42(8):657\u201368. https:\/\/doi.org\/10.1007\/s40261-022-01172-4.","journal-title":"Clin Drug Investig"},{"key":"622_CR60","doi-asserted-by":"publisher","unstructured":"Mura P, Cirri M, Faucci MT, Gin\u00e8s-Dorado JM, Bettinetti GP. Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. Journal of Pharmaceutical and Biomedical Analysis. 2002 Sep 5;30(2):227\u201337. https:\/\/doi.org\/10.1016\/S0731-7085(02)00252-2","DOI":"10.1016\/S0731-7085(02)00252-2"},{"key":"622_CR61","doi-asserted-by":"publisher","unstructured":"Thong MY, Manrique YJ, Steadman KJ. Drug loss while crushing tablets: Comparison of 24 tablet crushing devices. PLOS ONE. 2018 Mar 1;13(3):e0193683. https:\/\/doi.org\/10.1371\/journal.pone.0193683","DOI":"10.1371\/journal.pone.0193683"},{"key":"622_CR62","unstructured":"Exelixis, Inc. Soltamox - tamoxifene citrate, solution for oral administration (10mg\/5ml)\u2014clinical pharmacology review. Center for Drug Evaluation and Research-FDA; 2004."},{"key":"622_CR63","doi-asserted-by":"publisher","unstructured":"Ducray F, Ramirez C, Robert M, Maxime F, Bronnimann C, Chinot OL, et al. A bioequivalence study of a novel liquid and ready-to-use temozolomide oral suspension and temozolomide capsules in patients with primary tumors central nervous system malignancies. J Clin Oncol. 2022. Located at: world.  https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e22008","DOI":"10.1200\/JCO.2022.40.16_suppl.e22008"},{"key":"622_CR64","doi-asserted-by":"publisher","unstructured":"Cox DS, Allred A, Zhou Y, Infante JR, Gordon MS, Bendell J, et al. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors. Clin Pharmacol Drug Dev. 2015;4(4):287\u201394.  https:\/\/doi.org\/10.1002\/cpdd.152","DOI":"10.1002\/cpdd.152"},{"key":"622_CR65","unstructured":"AstraZeneca. Caprelsa - vandetanib, 100 and 300 mg tablets\u2014clinical pharmacology review. Center for Drug Evaluation and Research-FDA; 2010."},{"key":"622_CR66","doi-asserted-by":"publisher","unstructured":"Wang H, Long-Boyle J, Winger BA, Nicolaides T, Mueller S, Prados M, et al. Population pharmacokinetics of vemurafenib in children with recurrent\/refractory BRAF Gene V600E-mutant astrocytomas. J Clin Pharmacol. 2020;60(9):1209\u201319.  https:\/\/doi.org\/10.1002\/jcph.1617","DOI":"10.1002\/jcph.1617"},{"key":"622_CR67","doi-asserted-by":"publisher","unstructured":"Liu SN, Agarwal P, Heinig K, Datye A, Sturm-Pellanda C, Crugnola A, et al. Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling. Clin Transl Sci. 2023;16(6):1085\u201396.  https:\/\/doi.org\/10.1111\/cts.13515","DOI":"10.1111\/cts.13515"},{"key":"622_CR68","doi-asserted-by":"publisher","unstructured":"Sharma S, Pepin X, Cheung J, Zheng L, Wei H, Townsley D, et al. Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. Br J Clin Pharmacol. 2022;88(10):4573\u201384.  https:\/\/doi.org\/10.1111\/bcp.15362","DOI":"10.1111\/bcp.15362"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00622-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00622-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00622-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:35:04Z","timestamp":1790465704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00622-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":68,"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00622-0","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"18 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Pauline Claraz, C\u00e9cile Pineau, Coralie Guillemot, Etienne Chatelut, C\u00e9cile Arellano, and Florent Puisset declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data are available upon request from the authors.","order":5,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the conception and design of the study. Data collection was performed by Pauline Claraz; data analysis was performed by Pauline Claraz and Florent Puisset. The first draft of the manuscript was written by Pauline Claraz, Florent Puisset, and C\u00e9cile Arellano, and all authors commented on the previous versions of the manuscript. All authors attest to have read and approved the final submitted manuscript, and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}